Work

Abstract PO3-18-12: Results from a first-in-human study of DAN-222, a novel high-capacity drug conjugate in metastatic breast cancer as monotherapy and in combination with a PARPi [NCT05261269]

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs23-po3-18-12

Authors: Sara Hurvitz, Erika Hamilton, Timothy Pluard, Aki Morikawa, Hatem Soliman, Kay Yeung, Adam Brufsky, Amy Tiersten, Wajeeha Razaq, Kristen Foye, Timothy Hagerty

Institutions: Fred Hutch Cancer Center, Sarah Cannon, University of Missouri–Kansas City, University of Michigan, Moffitt Cancer Center, Moores Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Tisch Cancer Institute, University of Oklahoma Health Sciences Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396587394

Cites:

Cited by: 1

Related to: 10